Ziff Capital Partners led the Series 1 round in Stellular Bio.

Ziff Capital Partners, a private investment firm, led the Series 1 round in Stellular Bio, a biotechnology company, with participation from Cockrell Interests. The round will help advance Stellular's lead candidate, STLR-201, into clinical testing as a treatment for Sjogren's disease dry eye.